Alzheimer's Disease Clinical Trials in San Jose, CA

27 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases	—	xCures	13 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)	—	University of Southern California	16 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol	—	Indiana University	16 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	16 mi
An Objective Assessment Tool for Evaluating Functioning in Older Adults	—	Stanford University	16 mi
Assessing Cognitive Decline at Home	—	Stanford University	16 mi
Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia	N/A	Stanford University	16 mi
Bumetanide in Patients With Alzheimer's Disease	Phase 2	Stanford University	17 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	17 mi
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers	Phase 1/2	Ashvattha Therapeutics, Inc.	17 mi
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)	Phase 1	Onward Health, Inc	31 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	39 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	39 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease	Phase 2	Intra-Cellular Therapies, Inc.	40 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)	Phase 3	Bristol-Myers Squibb	41 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	41 mi
Senicapoc in Alzheimer's Disease	Phase 2	University of California, Davis	41 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	41 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	41 mi
Remotely-supervised Neuromodulation in PPA	N/A	University of Texas at Austin	42 mi
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project	—	University of Southern California	42 mi
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A	Early 1	University of Pennsylvania	42 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Life Molecular Imaging Ltd	42 mi
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	Phase 1/2	David Wilson	42 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	42 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	42 mi
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease	N/A	Neurobehavioral Systems, Inc.	43 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.